IL1A and systemic-onset juvenile idiopathic arthritis: Canakinumab (CAM; ACZ885; Ilaris®), a human IgG1 mAb that specifically targets IL-1β (binding dissociation constant 40 pmol/L) with no cross-reactivity to IL-1α or IL-1Ra, is currently used as an orphan drug for cryopyrin-associated periodic syndromes (CAPSs) and systemic-onset juvenile idiopathic arthritis (sJIA) (>2 years) (205, 206).